BioSpace News Archive

Biofrontera Inc. (Nasdaq: BFRI), announced today that the first subject has been enrolled in a Phase 1 study to evaluate the safety and tolerability of photodynamic therapy (PDT) for the treatment of actinic keratosis (AK) using three tubes of Ameluz® together with the company’s BF-RhodoLED® XL lamp.

Secura Bio, Inc. (Secura Bio) - (www.securabio.com), today announced that several abstracts relating to the Secura Bio product COPIKTRA® (duvelisib) will be presented at the 63rd annual meeting of the American Society of Hematology (ASH) in Atlanta, Georgia.

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), is pleased to announce functional data from their ALPHA-1062 intranasal Traumatic Brain Injury (TBI) program.

ESCAPE Bio, Inc., a clinical-stage company developing novel, precisely-targeted therapeutics for genetically-defined neurodegenerative diseases, today announced Mark Kaufmann has joined as Chief Financial Officer and Chief Business Officer.

Applied DNA Sciences, Inc. announced today a development in its cotton genomics program (the “Program”) that the Company believes can bring forensic proof of cotton authenticity and provenance specifically related to regional cotton varietals to give brands and relevant regulatory authorities access to fiber origin data regardless of location of manufacture.

Yarrow Biotechnology, Inc., an RTW-incubated company developing antisense oligonucleotide (ASO) therapeutics for severe, genetically defined CNS diseases, today announced the appointment of Dr. Mark T. Keating as Chief Scientific Officer.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company committed to being the leader in responsible pain management, announced that it has been named one of the Top Places to Work in Massachusetts in The Boston Globe’s 14th annual employee-based survey.

According to Emergen Research, the global wireless brain sensor market size was USD 391.7 million in 2020 and is expected to reach USD 804.3 million in 2028 and register a revenue CAGR of 9.5% during the forecast period, 2021-2028.

Bsense Bio Therapeutics Ltd., a FutuRx portfolio biopharmaceutical company dedicated to developing novel therapeutics for treatment of sensory hyperexcitability disorders, today announced positive topline data in a comparative preclinical study of its leading compound BSEN627 with pregabalin in chronic pain.

BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Natasha Drapeau, Executive Vice President of BioSig Technologies, Inc., would be presenting at the Benzinga All Access event on Tuesday, December 14, 2021, at 9:40 am EST.